{"news_desk": "Business", "print_page": "10", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Food and Drug Administration approves Opdivo, first immune-based treatment for lung cancer, produced by Bristol-Myers Squibb; drug is also known as nivolumab and could be used instead of conventional chemotherapy for some patients.", "type_of_material": "News", "word_count": "627", "lead_paragraph": "Opdivo, from Bristol-Myers Squibb, which harnesses the body\u2019s own immune system to attack tumors, was approved after strong results in a study.", "pub_date": "2015-03-05T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Lung Cancer Treatment Using Immune System Wins F.D.A. Approval", "print_headline": "F.D.A. Backs a Lung Cancer Therapy"}, "snippet": "Opdivo, from Bristol-Myers Squibb, which harnesses the body\u2019s own immune system to attack tumors, was approved after strong results in a study.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/03/05/business/lung-cancer-treatment-using-immune-system-wins-fda-approval.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Lung Cancer", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Bristol Myers Squibb Company", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Melanomas", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Merck & Company Inc", "name": "organizations"}], "blog": [], "_id": "54f7db1c38f0d8579fff618c", "source": "The New York Times"}